Table 1.
Currently approved, or soon to be evaluated, drug candidates of glucagon-like peptide-1 receptor agonists (GLP-1ra) (1) and sodium-glucose co-transporter 2 inhibitors (SGLT2-i) (2). Combination drugs containing GLP-1ra or SGLT2-i.
| Active ingredient | Status | Drug name |
|---|---|---|
| Exenatide (1) | Approved in EU (2006) | Byetta® |
| Liraglutide (1) | Approved in EU (2009) | Victoza® |
| Exenatide extended release (1) | Approved in EU (2011) | Bydureon® |
| Lixisenatide (1) | Approved in EU (2013) | Lyxumia® |
| Albiglutide (1) | Approved in EU (2014) | Eperzan®, Tanzeum® |
| Dulaglutide (1) | Approved in EU (2014) | Trulicity® |
| Liraglutide + Insulin degludec | Approved in EU (2016) | Xultophy® |
| Semaglutide (1) | Under development (phase III) | – |
| Dapagliflozin (2) | Approved in EU (2012) | Forxiga® |
| Canagliflozin (2) | Approved in EU i (2013) | Invokana® |
| Empagliflozin (2) | Approved in EU (2014) | Jardiance® |
| Dapagliflozin + Metformin | Approved in EU (2014) | Xigduo® |
| Canagliflozin + Metformin | Approved in EU (2014) | Vokanamet® |
| Empagliflozin + Metformin | Approved in EU (2015) | Synjardy® |
| Dapagliflozin + Saxagliptin | Approved in EU (2016) | Qtern® |
| Ipragliflozin (2) | Approved in Japan | (Suglat®) |
| Luseogliflozin (2) | Approved in Japan | (Lusefi®) |
| Tofogliflozin (2) | Approved in Japan | (Apleway®, Deberza®) |
| Sotagliflozin (2) | Under development (phase III) | – |
| Ertugliflozin (2) | Under development (phase III) | – |
| Remogliflozin etabonat (2) | Under development (phase IIb) | – |
EU, European Union; GLP-1ra, glucagon-like peptide-1 receptor agonist; SGLT2-i; sodium-glucose co-transporter 2 inhibitor.